Videos

The director for the Gene Therapy Institute at The Ohio State University talked about the latest developments in gene therapy for patients with Parkinson disease. [WATCH TIME: 4 minutes]

Expert neurologists share thoughts on how to improve patient/physician communication and how listening to the patient needs will aid in managing MG.

Drs Howard, Silvestri, Vu, Habib, and Stein comment on the role of pharmacists in managing MG, emphasizing educating both the pharmacists and the patients.

Expert neurologists discuss patient-focused care when it comes to treating MG, also highlighting clinical trials.

The director of the MedStar Georgetown Headache Center discussed the importance of maintaining hope and providing understanding of patients' frustrations in their treatment journey for migraine. [WATCH TIME: 5 minutes]

The vice president, Autoantibody Portfolio and Maternal Fetal Immunology Disease Area Leader, Johnson & Johnson, provided perspective on the unique molecular structure of nipocalimab seen across nonclinical and clinical studies. [WATCH TIME: 3 minutes]

Key opinion leaders emphasize the significance of early diagnosis in Alzheimer's disease, as it allows patients to make autonomous decisions and access early treatment options, including potential participation in clinical trials.

Sharon Cohen, MD, and Marwan Sabbagh, MD, differentiate between the preclinical, prodromal, and dementia stages of Alzheimer's disease (AD), and highlight known risk factors, including the contribution of ApoE gene polymorphism and copy numbers.

Drs Thorpy, Dogan, Doghramji, and Kushida talk about the use and uptake of newer narcolepsy treatments in clinical practice.

Experts in sleep medicine share their knowledge on abuse and dependency potential with newer narcolepsy treatment.

Ahmed Obeidat, MD, PhD, and Riley Bove, MD, review strategies for how to make drug classes and the risks-benefits profiles of individual agents accessible to patients.

Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, talk about the factors to consider when determining whether patients are candidates for anti-CD20 therapies.

The chief of the Division of MS and Neuroimmunology at UConn Health talked about the challenges with access to care in multiple sclerosis, particularly for marginalized communities, despite significant progress made in the field over the past decades. [WATCH TIME: 4 minutes]

Neurology News Network. for the week ending May 4, 2024. [WATCH TIME: 3 minutes]

The associate chair for technology and innovation at the NYU Grossman School of Medicine provided commentary on a study from AAN 2024 that examined the driving factors behind burnout in neurology departments. [WATCH TIME: 4 minutes]

The chief scientific officer of the Parkinson’s Foundation and chief executive officer of Tasso discussed their company partnership to expand and accelerate genetic research in Parkinson Disease. [WATCH TIME: 6 minutes]

In this segment, Kremens described pump therapies currently in development, such as ND0612 and ABBV-951.

Kremens gave thoughts on the use of several investigational continuous agents, including IPX203, risvodetinib, and P2B001.

The director for the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology provided an overview of the open-label extension of the phase 3 CHAMPION-NMOSD trial and how the newly approved ravulizumab fits with other NMOSD treatments. [WATCH TIME: 4 minutes]

The neurologist at Mass General Hospital talked about leveraging artificial intelligence to enhance clinical practice amidst growing demands and workforce shortages in neurology. [WATCH TIME: 4 minutes]

The director of the Alzheimer's Disease Care, Research and Education Program at the University of Rochester talked about recent results on the phase 3 ACCORD trial assessing AXS-05 for agitation in Alzheimer disease. [WATCH TIME: 8 minutes]

The chief medical officer at Biohaven provided insight on its investigational spinocerebellar ataxia agent troriluzole, the advantages of the newly developed SCACOMS measure, and how the therapy stacks against natural history data. [WATCH TIME: 4 minutes]

Neurology experts provide an overview of emerging treatments in MG, highlighting biomarkers and new routes of administration.

Experts in neurology discuss how to ensure disease progression in not due to poor adherence to treatment in MG, emphasizing educating the patient about their disease.

The professor of neurology at Mayo Clinic discussed the importance of standardizing MOG- antibody testing techniques and the need for effective treatments in patients living with MOGAD. [WATCH TIME: 3 minutes]

Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, review the benefits of exercise and physical activity in patients with MS. They also discuss strategies for talking to patients about the positive effects of lifestyle changes.

Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, talk about the importance of monitoring bladder dysfunction symptoms in MS care.

The professor of neurology at Mayo Clinic talked about MOG-antibody associated disease, a relatively newly recognized demyelinating condition of the central nervous system. [WATCH TIME: 4 minutes]

Neurology News Network. for the week ending April 27, 2024. [WATCH TIME: 3 minutes]

The associate professor of neurology at Harvard Medical School discussed findings from a study investigating nasal foralumab in patients with non-active secondary progressive multiple sclerosis. [WATCH TIME: 5 minutes]